ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 2382 • ACR Convergence 2025

    Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study

    Bana Shawareb1, Muhannad Haddadin1, lindsay Frumker2, Keri Ann Pfeil3, Meghan Gump3, Ansaam Daoud4 and Omer Pamuk5, 1Cleveland Clinic Akron General, Akron, OH, 2Case Western Reserve University, Cleveland, 3University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 4Case Western Reserve University/University Hospitals, Cleveland, OH, 5University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
  • Abstract Number: 0688 • ACR Convergence 2025

    Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study

    Benjamin Chaigne1, Alexandre bense2, Frédérique Aubourg3, Christian AGARD4, Yannick Allanore5, Alice berezne1, Gregory Pugnet6, Eric Hachulla7, Vincent Cottin8, Arnaud Hot8, bertrand Dunogue1, Anuxcy Kanagaratnam2, Sylvain Palat9, Alain Lescoat10, Sabine berthier11, Emmanuel Chatelus12, Sébastien Rivière13, David Launay14, Marie-Elise Truchetet15, Anh-Tuan Dinh-Xuan3 and Luc Mouthon1, 1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 2AP HP, Paris, France, 3Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5Université Paris Cité, Paris, France, 6CHU, Montpelliers, France, 7CHU, Lilles, France, 8CHU, Lyon, France, 9Limoges, Limoges, France, 10CHU Rennes - University Rennes, Rennes, France, 11CHU, Dijon, France, 12Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 13AP HP, Parsi, France, 14Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 15Bordeaux University Hospital, Bordeaux, France

    Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
  • Abstract Number: 0037 • ACR Convergence 2025

    A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors

    Natalie McCormick1, Sharan Rai2, Chio Yokose3, Tony Merriman4, Robert Terkeltaub5 and Hyon K. Choi6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital/Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Waltham, MA, 4University of Alabama at Birmingham, Homewood, AL, 5Retired, San Diego, CA, 6MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
  • Abstract Number: 2237 • ACR Convergence 2025

    Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis

    Gabriella Girolami1, Shamey Kassim2, Alexander Peterson3, Aaron Baraff3, Alexandra Schmidt3, Shailender Bhatia4, Natalie Miller4, Jennifer Barton5, Jeffrey Curtis6, Christopher Li4 and Namrata Singh7, 1University of Washington, Seattle, 2University of Washington, Seattle, WA, 3VA Puget Sound Health Care System, Seattle, WA, 4Fred Hutch Cancer Center, Seattle, 5VA Portland Health Care System/OHSU, Portland, OR, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 7University of Washington, Bellevue, WA

    Background/Purpose: While disease-modifying anti-rheumatic drugs (DMARDs) are critical in managing rheumatoid arthritis (RA), their immunosuppressive effects raise concerns about cancer-related outcomes. In patients with RA…
  • Abstract Number: 0682 • ACR Convergence 2025

    Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

    Alex Luta1, Saloni Mitchell2 and Virginia Steen3, 1Hospital for Special Surgery, New York, NY, 2Mount Sinai West and Morningside, New York, NY, 3Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
  • Abstract Number: 2086 • ACR Convergence 2025

    WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials

    Dawn McGuire1, Alan Brett2, Neil Segal3, Meghan Miller4, David Rosen1 and Yoshi Kumagai5, 1OrthoTrophix, Inc, Foster City, CA, 2Imorphics, Manchester M20 2HJ, England, United Kingdom, 3KUMC, Kansa City, KS, 4OrthoTrophics, Foster City, CA, 5OrthoTrophix, Foster City, CA

    Background/Purpose: TPX-100, a peptide derived from matrix extracellular phosphoglycoprotein (MEPE), is in development as a potential disease-modifying osteoarthritis drug (DMOAD) for mild to severe knee…
  • Abstract Number: 0638 • ACR Convergence 2025

    Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era

    Takehiro Nakai1, Sho Fukui2, Yukihiko Ikeda3, Masei Suda4, Hiromichi Tamaki1, mitsumasa kishimoto5 and Masato Okada6, 1Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 2Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 3St Luke's international hospital in Japan, Tokyo, Japan, 4Suwa Central Hospital, Nagano, Japan, 5Kyorin University School of Medicine, Tokyo, Japan, 6St. Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
  • Abstract Number: 1911 • ACR Convergence 2025

    Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

    Victoria Konzett1, Eva Manger2, Simon Reider2, Johannes Griss3, Constanze Jonak3, Kastriot Kastrati4, Peter Mandl4, Gudrun Ratzinger5, Christina Duftner2, Thomas Karonitsch4 and Daniel Aletaha6, 1Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, 3Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, 4Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 5Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, 6Medical University Vienna, Wien, Austria

    Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
  • Abstract Number: 0628 • ACR Convergence 2025

    Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus

    Panagiotis Garantziotis1, Dionysis Nikolopoulos2, Spyridon Katechis3, Alp Temiz4, Danae-Mona Nöthling1, Christina Adamichou5, Prodromos Sidiropoulos6, Georg Schett7, Fanouriakis Antonis3, Dimitrios Boumpas8 and George Bertsias9, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 4Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 5Medical School University of Crete, Heraklion, Greece, Heraklion, Germany, 6Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, 9Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece

    Background/Purpose: Organ damage drives morbidity and mortality in systemic lupus erythematosus (SLE), yet no validated tools exist to predict early damage. We aimed to develop…
  • Abstract Number: 0722 • ACR Convergence 2024

    Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis

    Andrea Hinojosa-Azaola1, Marlon Sandino-Bermúdez2, Ana Sarahí Mulia-Soto3, Juan M. Mejía-Vilet4 and Eduardo Martin Nares5, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, 4Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
  • Abstract Number: 2048 • ACR Convergence 2024

    Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study

    Maximilian Gysan1, Svitlana Pochepnia2, Helmut Prosch2, Antje Lehmann1, Silvia Lee1, Andreas Renner1, Daniela Gompelmann3, Marco Idzko1, Iris Aykara4, Karolina Anderle4, Peter Weber4, Hans Kiener4, Michael Bonelli4, Daniel Mrak4, Daniel Aletaha5, Helga Lechner-Radner4 and Kastriot Kastrati4, 1Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 2Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 3Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria., Vienna, Austria, 4Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria

    Background/Purpose: The prognostic value of bronchoalveolar lavage (BAL) in connective tissue disease-related interstitial lung disease (CTD-ILD) is currently underexplored, resulting in a lack of understanding…
  • Abstract Number: 2558 • ACR Convergence 2024

    Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand

    Patapong Towiwat1, Wichittra Tassaneeyakul2, Suppachai Lawanaskol3, Chonlaphat Sukasem4, Nontaya Nakkam2, Ticha Rerkpattanapipat4, Jettanong Klaewsongkram5, Pawinee Rerknimitr5, Duangkamon Poolpun6, Worawit Louthrenoo7 and Niwat Saksit8, 1Naresuan university, Phitsanulok, Thailand, 2Khon Kaen university, Khon Kaen, Thailand, 3Chaiprakan hospital, Chiang Mai, Thailand, 4Mahidol university, Bangkok, Thailand, 5Chulalongkorn university, Bangkok, Thailand, 6Buddhachinaraj hospital, Phitsanulok, Thailand, 7Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, 8Phayao university, Phayao, Thailand

    Background/Purpose: Severe allopurinol hypersensitivity (SAH), although uncommon, is a serious adverse event of allopurinol.  Both genetic (HLA-B*58:01) and non-genetic factors (female gender, age ≥60-65 years,…
  • Abstract Number: 0738 • ACR Convergence 2024

    Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA

    Colm Kirby1, Rachael Flood1, Sharon Cowley2, Emma Finlay3, Ronan Mullan1, Grainne Murphy4 and David Kane5, 1Tallaght University Hospital, DUBLIN, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3School of Biotechnology, Dublin City University, Dublin, Ireland, 4Cork University Hospital, Cork, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland

    Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…
  • Abstract Number: 2083 • ACR Convergence 2024

    A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy

    Yun Kyu Kim1, Ju yeon Kim2, Jung Yoon Pyo3, Min Jung Kim4, Jin Kyun Park5, Eun Young Lee6, Yun Jong lee3, eun Bong Lee1 and Jun Won park2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 3Seoul National University Bundang Hospital, Seongnam-si, 4Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, 5Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 63Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Previous studies have demonstrated that idiopathic inflammatory myopathy (IIM) is associated with an elevated cancer risk. However, there is limited evidence on the specific…
  • Abstract Number: 2561 • ACR Convergence 2024

    Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

    Natalie McCormick1, Amit Joshi2, Robert Terkeltaub3, Tony Merriman4, Matthew Nayor5, Chio Yokose6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Channing Division of Network Medicine, Boston, MA, 3Retired, San Diego, CA, 4University of Alabama at Birmingham, Homewood, AL, 5Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 6Massachusetts General Hospital, Waltham, MA, 7Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout.  A previous cross-sectional study of pre-existing gout (n=330…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology